A GAO report examines the “extraordinary” price increases of brand-name drugs. Some of these increases are very, very large, but many are made by repackagers, not the original manufacturer. Many of the drugs were relatively low-priced to start and there were some understandable reasons for the increases.
http://www.washingtonpost.com/wp-dyn/content/article/2010/01/11/AR2010011102231.html